The PRISMS study. Interferon-β 1a (Rebif) in intermittent multiple sclerosis;Die PRISMS-studie. Interferon-β 1a (Rebif®) bei schubformiger multipler sklerose

Nervenarzt

Volumn 70, Issue 2, 1999, Pages 182-185

  Hartung, H P ^a   Flachenecker, P ^b   Weilbach, F X ^b   Rieckmann, P ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON;

ARTICLE; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; HUMAN; MULTIPLE SCLEROSIS;

ADJUVANTS, IMMUNOLOGIC; ADULT; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033066213     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001150050421     Document Type: Article

References (9)

1. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
2. Paty DW, LI DK (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multi center, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43:662-667
3. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis.The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294
4. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL et al (1998) Magnetic resonance studies of intramuscular interferon-β-1a for relapsing multiple sclerosis. Ann Neurol 43:79-87
5. PRISMS (Prevention of Relapses and Disability by Interferon-beta 1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis. Lancet 352:1498-1504
6. Li DKB, Paty D, U.B.C. MS/MRI Analysis Research Group and the PRISMS (Prevention of Relapses and Disability by Interferon-beta 1a Subcutaneously in Multiple Sclerosis) Study Group (1999) Randomised, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis: MRI results. Ann Neurol (in press)
7. Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttmann B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE III, Coofair DL, Simon JH, Jacobs LD, and the Multiple Sclerosis Collaborative Research Group (MSCRG) (1998) Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50:1266-1272
8. Cross AH, Antel JP (1998) Antibodies to beta-interferons in multiple sclerosis. Can we neutralize the controversy? Neurology 50:1206-1208
9. Walter EU, Dang T, Hartung HP, Hohlfeld R (1997) Bildung von neutralisierenden Antikörpern unter Therapie der multiplen Sklerose mit Interferon beta-1b: Praktisches Vorgehen bei Verdacht auf Therapieversagen. Nervenarzt 68:935-939